Skip to content

Construction and validation of SAPHO syndrome classification based on pathogenesis

Construction and validation of SAPHO syndrome classification based on pathogenesis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126665
Enrollment
Unknown
Registered
2026-06-12
Start date
2026-06-12
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SAPHO syndrome

Interventions

SAPHO syndrome patients:None

Sponsors

The First Medical Center of the People's Liberation Army General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patient's age should be between 18 and 65 years old; 2. The patient should meet the recognized diagnostic criteria for SAPHO syndrome by Kahn (2003), i.e. Any one of the following four conditions can be used for diagnosis: (1) Bone and/or joint disease accompanied by palmoplantar pustulosis; (2) Bone and/or joint disease accompanied by severe acne; (3) Adult isolated aseptic osteoporosis or osteitis (excluding Propionibacterium acnes); (4) Chronic recurrent multifocal osteomyelitis in children; 3. The patient has signed an informed consent form, agreeing to use their stock serum, blood cell samples, and clinical data for scientific research.

Exclusion criteria

Exclusion criteria: 1. Patients with other clearly defined autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis) that may have interfering factors affecting the experimental results; 2. Patients with a history of infectious diseases, cardiovascular and cerebrovascular diseases, active malignant tumors, as well as high-risk populations such as pregnant women, emergency patients, end-stage disease patients, and elderly patients with underlying diseases; 3. Individuals with insufficient or low-quality blood samples that cannot be used for DNA extraction.

Design outcomes

Primary

MeasureTime frame
Human Leukocyte Antigen B27;NCSTN gene;PSTPIP2 gene;

Countries

China

Contacts

Public ContactWang Rui

The First Medical Center of the People's Liberation Army General Hospital

wr0699@163.com+86 152 1083 9279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026